Fortress Biotech Inc
Fortress Biotech Inc (FBIO) is a small-cap biopharmaceutical company that acquires, develops and seeks to commercialise a portfolio of pharmaceutical and biotechnology products, typically through subsidiary companies. Its model centres on advancing clinical- and preclinical-stage programmes while leveraging partnerships and licensing to move assets through regulatory pathways. With a market capitalisation around $82 million, the stock is typically volatile and may be sensitive to trial results, regulatory decisions and financing activity. Potential upside can come from successful clinical data, approvals or strategic deals, but investors should be mindful of patent, regulatory and liquidity risks, plus the possibility of dilution from future fundraising. This summary is educational only and not personalised financial advice; consider your time horizon, risk tolerance and the company’s pathway before considering any exposure.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Fortress Biotech's stock with a target price of $26.25, indicating significant growth potential.
Financial Health
Fortress Biotech is generating solid revenue and cash flow, indicating a strong financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FBIO
Thrill & Excitement Fund
Ready for an investing adventure? This collection features carefully selected stocks with explosive growth potential. Our professional analysts have identified companies at the cutting edge of space tourism, biotech breakthroughs, and digital gaming — all poised to potentially redefine their industries.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diversified development pipeline
The company advances multiple programmes across subsidiaries, so positive trial news or licences can materially shift prospects — though outcomes vary and setbacks are common.
Clinical catalysts ahead
Upcoming data readouts or regulatory steps can create significant share-price movement; these catalysts bring opportunity but also heightened binary risk.
Capital and dilution risk
As a small-cap biotech, Fortress may need additional funding to progress its pipeline, which could dilute existing shareholders and affect share price.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
